Drug Survival of Systemic and Biologic Monotherapy Treatments for Pityriasis Rubra Pilaris: A Retrospective Observational Study

2021 ◽  
Author(s):  
Caroline Kettering ◽  
Hasan Khosravi ◽  
Camila Ortiz ◽  
Joseph C. English
Keyword(s):  
Observational Study ◽  
Retrospective Observational Study ◽  
Drug Survival ◽  
Pityriasis Rubra Pilaris ◽  
Biologic Monotherapy

Long‐term safety and drug survival of acitretin in psoriasis: a retrospective observational study

2018 ◽  
Vol 58 (5) ◽  
pp. 593-599 ◽  
Author(s):  
Leena Chularojanamontri ◽  
Narumol Silpa‐archa ◽  
Chanisada Wongpraparut ◽  
Pichaya Limphoka
Keyword(s):  
Observational Study ◽  
Retrospective Observational Study ◽  
Drug Survival

scholarly journals EQ-5D utility, response and drug survival in rheumatoid arthritis patients on biologic monotherapy: A prospective observational study of patients registered in the south Swedish SSATG registry

PLoS ONE ◽  
2017 ◽  
Vol 12 (2) ◽  
pp. e0169946 ◽  
Author(s):  
Tanja Schjødt Jørgensen ◽  
Carl Turesson ◽  
Meliha Kapetanovic ◽  
Martin Englund ◽  
Aleksandra Turkiewicz ◽  
...  
Keyword(s):  
Rheumatoid Arthritis ◽  
Observational Study ◽  
Prospective Observational Study ◽  
The South ◽  
Drug Survival ◽  
Biologic Monotherapy

Hemmkörperentwicklung bei Hämophilie-Patienten nach Präparate wechsel

2012 ◽  
Vol 32 (S 01) ◽  
pp. S39-S42 ◽  
Author(s):  
S. Kocher ◽  
G. Asmelash ◽  
V. Makki ◽  
S. Müller ◽  
S. Krekeler ◽  
...  
Keyword(s):  
Risk Factors ◽  
Risk Factor ◽  
Observational Study ◽  
Retrospective Observational Study ◽  
Frequent Change ◽  
Patient Age ◽  
Treatment Regimens ◽  
Patient Âgé ◽  
The Relationship ◽  
Observation Period

SummaryThe retrospective observational study surveys the relationship between development of inhibitors in the treatment of haemophilia patients and risk factors such as changing FVIII products. A total of 119 patients were included in this study, 198 changes of FVIII products were evaluated. Results: During the observation period of 12 months none of the patients developed an inhibitor, which was temporally associated with a change of FVIII products. A frequent change of FVIII products didn’t lead to an increase in inhibitor risk. The change between plasmatic and recombinant preparations could not be confirmed as a risk factor. Furthermore, no correlation between treatment regimens, severity, patient age and comorbidities of the patients could be found.

Sign in / Sign up

Export Citation Format

Share Document